AngioDynamics, Inc. $ANGO Shares Purchased by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC increased its stake in AngioDynamics, Inc. by 71.8%, acquiring an additional 97,123 shares and holding 232,473 shares total, valued at approximately $2.18 million.
• Several hedge funds, including ProShare Advisors LLC and Graham Capital Management, recently purchased stakes in AngioDynamics, highlighting strong interest from institutional investors, who now own 89.43% of the stock.
• In their latest earnings report, AngioDynamics exceeded analyst expectations with a loss of ($0.03) per share and revenue of $80.16 million, a 13.0% increase year-over-year, while analysts predict a consensus target price of $19.00 for the stock.

Cubist Systematic Strategies LLC boosted its position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 71.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 232,473 shares of the medical instruments supplier's stock after purchasing an additional 97,123 shares during the period. Cubist Systematic Strategies LLC owned about 0.57% of AngioDynamics worth $2,183,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. ProShare Advisors LLC acquired a new stake in AngioDynamics during the 4th quarter valued at $100,000. Graham Capital Management L.P. acquired a new stake in AngioDynamics during the 4th quarter valued at $106,000. Cerity Partners LLC grew its holdings in AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock valued at $121,000 after buying an additional 2,333 shares during the last quarter. GAMMA Investing LLC grew its holdings in AngioDynamics by 1,281.4% during the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock valued at $130,000 after buying an additional 12,891 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in AngioDynamics during the 1st quarter valued at $139,000. Institutional investors and hedge funds own 89.43% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wall Street Zen upgraded AngioDynamics from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Lake Street Capital assumed coverage on AngioDynamics in a report on Wednesday, July 16th. They set a "buy" rating and a $24.00 target price on the stock. Canaccord Genuity Group increased their target price on AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 16th. Finally, HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of AngioDynamics in a report on Wednesday, July 16th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $19.00.

AngioDynamics Stock Down 2.8%

Shares of ANGO stock traded down $0.31 during mid-day trading on Friday, hitting $10.65. 534,075 shares of the company's stock were exchanged, compared to its average volume of 352,209. AngioDynamics, Inc. has a fifty-two week low of $5.83 and a fifty-two week high of $13.50. The stock has a 50-day simple moving average of $9.41 and a two-hundred day simple moving average of $9.59. The stock has a market cap of $432.71 million, a price-to-earnings ratio of -12.83 and a beta of 0.64.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.The firm had revenue of $80.16 million for the quarter, compared to analysts' expectations of $74.26 million. During the same quarter last year, the firm earned ($0.06) earnings per share. The firm's revenue for the quarter was up 13.0% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. As a group, analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.